References
- Compston A, Coles A. Multiple sclerosis. Lancet. 2008 Oct 25;372(9648):1502–1517.
- Brichetto G, Messmer Uccelli M, Mancardi GL, et al. Symptomatic medication use in multiple sclerosis. Mult Scler. 2003 Oct;9(5):458–460.
- Foley PL, Vesterinen HM, Laird BJ, et al. Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis. Pain. 2013 May;154(5):632–642.
- Khan F, Pallant J. Chronic pain in multiple sclerosis: prevalence, characteristics, and impact on quality of life in an Australian community cohort. J Pain. 2007 8;Aug(8):614–623.
- Loeser JD, Treede RD. The Kyoto protocol of IASP Basic Pain Terminology. Pain. 2008 Jul 31;137(3):473–477.
- Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008 Apr 29;70(18):1630–1635.
- Scholz J, Finnerup NB, Attal N, et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019 Jan;160(1):53–59.
- Solaro C, Brichetto G, Amato MP, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology. 2004 Sep 14;63(5):919–921.
- Khan F, Pallant JF, Amatya B, et al. Cognitive-behavioral classifications of chronic pain in patients with multiple sclerosis. Int J Rehabil Res. 2011 Sep;34(3):235–242.
- Brola W, Mitosek-Szewczyk K, Opara J. Symptomatology and pathogenesis of different types of pain in multiple sclerosis. Neurol Neurochir Pol. 2014;48(4):272–279.
- O’Connor AB, Schwid SR, Herrmann DN, et al. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain. 2008 Jul;137(1):96–111.
- Simons LE, Elman I, Borsook D. Psychological processing in chronic pain: a neural systems approach. Neurosci Biobehav Rev. 2014 Feb;39:61–78.
- Seixas D, Palace J, Tracey I. Chronic pain disrupts the reward circuitry in multiple sclerosis. Eur J Neurosci. 2016 Aug;44(3):1928–1934.
- Truini A, Barbanti P, Pozzilli C, et al. A mechanism-based classification of pain in multiple sclerosis. J Neurol. 2013 Feb;260(2):351–367.
- Amatya B, Young J, Khan F. Non-pharmacological interventions for chronic pain in multiple sclerosis. Cochrane Database Syst Rev. 2018 Dec;19(12):CD012622.
- Seixas D, Foley P, Palace J, et al. Pain in multiple sclerosis: a systematic review of neuroimaging studies. Neuroimage Clin. 2014;5:322–331.
- Monteleone F, Nicoletti CG, Stampanoni Bassi M, et al. Nerve growth factor is elevated in the CSF of patients with multiple sclerosis and central neuropathic pain. J Neuroimmunol. 2018 Jan;15(314):89–93.
- Harrison AM, McCracken LM, Bogosian A, et al. Towards a better understanding of MS pain: a systematic review of potentially modifiable psychosocial factors. J Psychosom Res. 2015 Jan;78(1):12–24.
- Sheng J, Liu S, Wang Y, et al. The Link between Depression and Chronic Pain: neural Mechanisms in the Brain. Neural Plast. 2017;2017:9724371.
- Martinelli Boneschi F, Colombo B, Annovazzi P, et al. Lifetime and actual prevalence of pain and headache in multiple sclerosis. Mult Scler. 2008 May;14(4):514–521.
- Morales Y, Parisi JE, Lucchinetti CF. The pathology of multiple sclerosis: evidence for heterogeneity. Adv Neurol. 2006;98:27–45.
- Al-Araji AH, Oger J. Reappraisal of Lhermitte’s sign in multiple sclerosis. Mult Scler. 2005 Aug;11(4):398–402.
- Urits I, Adamian L, Fiocchi J, et al. Advances in the Understanding and Management of Chronic Pain in Multiple Sclerosis: a Comprehensive Review. Curr Pain Headache Rep. 2019 Jul 25;23(8):59.
- Ferraro D, Annovazzi P, Moccia M, et al. Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: an Italian multi-centre study. Mult Scler Relat Disord. 2019 Oct;19(37):101461.
- Cruccu G, Gronseth G, Alksne J, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008 Oct;15(10):1013–1028.
- Minagar A, Sheremata WA. Glossopharyngeal neuralgia and MS. Neurology. 2000 Mar 28;54(6):1368–1370.
- Nurmikko TJ, Gupta S, Maclver K. Multiple sclerosis-related central pain disorders. Curr Pain Headache Rep. 2010 Jun;14(3):189–195.
- Hugos CL, Cameron MH. Assessment and Measurement of Spasticity in MS: state of the Evidence. Curr Neurol Neurosci Rep. 2019 Aug 30;19(10):79.
- Hughes C, Howard IM. Spasticity management in multiple sclerosis. Phys Med Rehabil Clin N Am. 2013 Nov;24(4):593–604.
- Izquierdo G. Multiple sclerosis symptoms and spasticity management: new data. Neurodegener Dis Manag. 2017 Nov;7:(6s):7–11.
- Fragoso YD, Adoni T, Alves-Leon SV, et al. Migraine in 746 patients with multiple sclerosis. Arq Neuropsiquiatr. 2019;77(9):617–621.
- Gurkan MA, Gurkan FT. Measurement of Pain in Multiple Sclerosis. Noro Psikiyatr Ars. 2018;55(Suppl 1):S58–S62.
- Reed MD, Van Nostran W. Assessing pain intensity with the visual analog scale: a plea for uniformity. J Clin Pharmacol. 2014 Mar;54(3):241–244.
- Borjeson S, Hursti TJ, Peterson C, et al. Similarities and differences in assessing nausea on a verbal category scale and a visual analogue scale. Cancer Nurs. 1997 Aug;20(4):260–266.
- Ware LJ, Epps CD, Herr K, et al. Evaluation of the Revised Faces Pain Scale, Verbal Descriptor Scale, Numeric Rating Scale, and Iowa Pain Thermometer in older minority adults. Pain Manag Nurs. 2006 Sep;7(3):117–125.
- Main CJ. Pain assessment in context: a state of the science review of the McGill pain questionnaire 40 years on. Pain. 2016 Jul;157(7):1387–1399.
- Kahraman T, Ozdogar AT, Ertekin O, et al. Frequency, type, distribution of pain and related factors in persons with multiple sclerosis(). Mult Scler Relat Disord. 2019 Feb;28:221–225.
- Osborne TL, Raichle KA, Jensen MP, et al. The reliability and validity of pain interference measures in persons with multiple sclerosis. J Pain Symptom Manage. 2006 Sep;32(3):217–229.
- Ehde DM, Nitsch KP, Smiley JP. Measurement characteristics and clinical utility of the Brief Pain Inventory-Short Form for individuals with multiple sclerosis. Rehabil Psychol. 2015 Nov;60(4):365–366.
- Meseguer-Henarejos AB, Sanchez-Meca J, Lopez-Pina JA, et al. Inter- and intra-rater reliability of the Modified Ashworth Scale: a systematic review and meta-analysis. Eur J Phys Rehabil Med. 2018 Aug;54(4):576–590.
- Aboud T, Schuster NM. Pain Management in Multiple Sclerosis: a Review of Available Treatment Options. Curr Treat Options Neurol. 2019Nov27;21(12):62.
- Solaro C, Brichetto G, Battaglia MA, et al. Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. Neurol Sci. 2005 Feb;25(6):307–310.
- Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia. Use of side effects. Arch Neurol. 1968 Aug;19(2):129–136.
- Rossi S, Mataluni G, Codeca C, et al. Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. Eur J Neurol. 2009 Mar;16(3):360–366.
- Corrigan R, Derry S, Wiffen PJ, et al. Clonazepam for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012 May;16(5):CD009486.
- Cendrowski W, Sobczyk W. Clonazepam, baclofen and placebo in the treatment of spasticity. Eur Neurol. 1977;16(1–6):257–262.
- Food and Drug Administration (FDA). Neurontin® (gabapentin) Capsules. [cited 2020 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf
- Kukkar A, Bali A, Singh N, et al. Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res. 2013 Mar;36(3):237–251.
- Houtchens MK, Richert JR, Sami A, et al. Open label gabapentin treatment for pain in multiple sclerosis. Mult Scler. 1997 Aug;3(4):250–253.
- European Medicines Agency (EMA). Gapapentin. [cited 2020 Apr 9]. Available from: https://www.ema.europa.eu/en/documents/psusa/gabapentin-list-nationally-authorised-medicinal-products-psusa/00001499/201902_en.pdf
- Calandre EP, Rico-Villademoros F, Slim M. Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. Expert Rev Neurother. 2016 Nov;16(11):1263–1277.
- Solaro C, Boehmker M, Tanganelli P. Pregabalin for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. J Neurol. 2009 Oct;256(10):1773–1774.
- Solaro C, Tanganelli P. Acute delirium in patients with multiple sclerosis treated with pregabalin. Clin Neuropharmacol. 2009 Jul-Aug;32(4):236–237.
- Solaro CM, Ferriero G. Refactory Trigeminal Neuralgia successfully treated by combination therapy (Pregabalin plus Lamotrigine). Mult Scler Relat Disord. 2018 Oct;25:165–166.
- Onakpoya IJ, Thomas ET, Lee JJ, et al. Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials. BMJ Open. 2019 Jan 21;9(1):e023600.
- European Medicines Agency (EMA). Pregabalin. [cited 2020 Apr 9]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica
- Food and Drug Administration (FDA). Pregabalin (Lyrica®). [cited 2020 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021446s035,022488s013lbl.pdf
- Walden J, Grunze H, Bingmann D, et al. Calcium antagonistic effects of carbamazepine as a mechanism of action in neuropsychiatric disorders: studies in calcium dependent model epilepsies. Eur Neuropsychopharmacol. 1992 Dec;2(4):455–462.
- Johannessen Landmark C, Larsson PG, Rytter E, et al. Antiepileptic drugs in epilepsy and other disorders–a population-based study of prescriptions. Epilepsy Res. 2009 Nov;87(1):31–39.
- Zakrzewska JM, Wu J, Brathwaite TS. A Systematic Review of the Management of Trigeminal Neuralgia in Patients with Multiple Sclerosis. World Neurosurg. 2018 Mar;111:291–306.
- Reder AT, Arnason BG. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology. 1995 Jun;45(6):1097–1100.
- Liu J, Zhang Q, Lian Z, et al. Painful tonic spasm in neuromyelitis optica spectrum disorders: prevalence, clinical implications and treatment options. Mult Scler Relat Disord. 2017 Oct;17:99–102.
- European Medicines Agency (EMA). Carbamazepine. [cited 2020 Apr 9]. Available from: https://www.ema.europa.eu/en/documents/product-information/zebinix-epar-product-information_en.pdf
- Food and Drug Administration (FDA). Carbamazepine (Tegretol®). [cited 2020 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016608s101,018281s048lbl.pdf
- Yamatogi Y. Principles of antiepileptic drug treatment of epilepsy. Psychiatry Clin Neurosci. 2004 Jun;58(3):S3–6.
- Wiffen PJ, Derry S, Moore RA. Lamotrigine for acute and chronic pain. Cochrane Database Syst Rev. 2011 Feb;16(2):CD006044.
- Breuer B, Pappagallo M, Knotkova H, et al. A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clin Ther. 2007 Sep;29(9):2022–2030.
- Ramsaransing G, Zwanikken C, De Keyser J. Worsening of symptoms of multiple sclerosis associated with carbamazepine. BMJ. 2000 Apr 22;320(7242):1113.
- Leandri M, Lundardi G, Inglese M, et al. Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis. J Neurol. 2000 Jul;247(7):556–558.
- Food and Drug Administration (FDA). Lamotrigine (LAMICTAL®). [cited 2020 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022251,020764s029,020241s036lbl.pdf
- Hirata-Koizumi M, Saito M, Miyake S, et al. Adverse events caused by drug interactions involving glucuronoconjugates of zidovudine, valproic acid and lamotrigine, and analysis of how such potential events are discussed in package inserts of Japan, UK and USA. J Clin Pharm Ther. 2007 Apr;32(2):177–185.
- European Medicines Agency (EMA). Lamotrigine. [cited 2020 Apr 9]. Available from: https://www.ema.europa.eu/en/documents/referral/lamictal-article-30-referral-annex-i-ii-iii_en.pdf
- Wiffen PJ, Derry S, Moore RA, et al. Levetiracetam for neuropathic pain in adults. Cochrane Database Syst Rev. 2014 7;Jul(7):CD010943.
- Falah M, Madsen C, Holbech JV, et al. A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis. Eur J Pain. 2012 Jul;16(6):860–869.
- Food and Drug Administration (FDA). Levetiracetam (KEPPRA®). [cited 2020 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021035s078s080,021505s021s024lbl.pdf
- European Medicines Agency (EMA). INN-levetiracetam. [cited 2020 Apr 9]. Available from: https://www.ema.europa.eu/en/documents/product-information/keppra-epar-product-information_en.pdf
- D’Aleo G, Sessa E, Di Bella P, et al. Topiramate modulation of R3 nociceptive reflex in multiple sclerosis patients suffering paroxysmal symptoms. J Neurol. 2001 Nov;248(11):996–999.
- Siniscalchi A, Gallelli L, De Sarro G. Effects of topiramate on dysaesthetic pain in a patient with multiple sclerosis. Clin Drug Investig. 2013 Feb;33(2):151–154.
- Food and Drug Administration (FDA). Topiramate (Topamax®). [cited 2020 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020505s057_020844s048lbl.pdf
- European Medicines Agency (EMA). Topiramate. [cited 2020 Apr 9]. Available from: https://www.ema.europa.eu/en/documents/referral/topamax-article-30-referral-annex-i-ii-iii_en.pdf
- Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 Feb;14(2):162–173.
- Shelton RC. Serotonin and Norepinephrine Reuptake Inhibitors. Handb Exp Pharmacol. 2019;250:145–180.
- Vollmer TL, Robinson MJ, Risser RC, et al. A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis. Pain Pract. 2014 Nov;14(8):732–744.
- Brown TR, Slee A. A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis. Int J MS Care. 2015 Mar-Apr;17(2):83–89.
- European Medicines Agency (EMA). Duloxetine. [cited 2020 Apr 9]. Available from: https://www.ema.europa.eu/en/documents/overview/cymbalta-epar-summary-public_en.pdf
- Food and Drug Administration (FDA). Duloxetine hydrochloride (Cymbalta®). [cited 2020 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022516lbl.pdf
- Sindrup SH. Tricyclic antidepressants in “central pain”. Acta Neurol Scand. 1991 Aug;84(2):171–172.
- Chitsaz A, Janghorbani M, Shaygannejad V, et al. Sensory complaints of the upper extremities in multiple sclerosis: relative efficacy of nortriptyline and transcutaneous electrical nerve stimulation. Clin J Pain. 2009 May;25(4):281–285.
- Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2005 Jul;20(3):CD005454.
- Burchiel KJ, Hsu FP. Pain and spasticity after spinal cord injury: mechanisms and treatment. Spine (Phila Pa 1976). 2001 Dec 15;26(24 Suppl):S146–60.
- Shaikh A, Phadke CP, Ismail F, et al. Relationship Between Botulinum Toxin, Spasticity, and Pain: a Survey of Patient Perception. Can J Neurol Sci. 2016 Mar;43(2):311–315.
- Bakheit AM. The possible adverse effects of intramuscular botulinum toxin injections and their management. Curr Drug Saf. 2006 Aug;1(3):271–279.
- Jawahar R, Oh U, Yang S, et al. A systematic review of pharmacological pain management in multiple sclerosis. Drugs. 2013 Oct;73(15):1711–1722.
- Rudroff T. Cannabis for Neuropathic Pain in Multiple Sclerosis-High Expectations, Poor Data. Front Pharmacol. 2019;10:1239.
- Walker JM, Hohmann AG, Martin WJ, et al. The neurobiology of cannabinoid analgesia. Life Sci. 1999;65(6–7):665–673.
- Quartilho A, Mata HP, Ibrahim MM, et al. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology. 2003 Oct;99(4):955–960.
- Ibrahim MM, Rude ML, Stagg NJ, et al. CB2 cannabinoid receptor mediation of antinociception. Pain. 2006 May;122(1–2):36–42.
- Patti F, Messina S, Solaro C, et al. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):944–951.
- Vermersch P, Tetrahydrocannabinol: TM. Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice. Eur Neurol. 2016;76(5–6):216–226.
- Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005 Sep 27;65(6):812–819.
- Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013 Apr;260(4):984–997.
- Ferre L, Nuara A, Pavan G, et al. Efficacy and safety of nabiximols (Sativex((R))) on multiple sclerosis spasticity in a real-life Italian monocentric study. Neurol Sci. 2016 Feb;37(2):235–242.
- Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004 Aug;10(4):434–441.
- Gajofatto A. Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis. Mult Scler Relat Disord. 2016 Jul;8:64–65.
- Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004 Jul 31;329(7460):253.
- Messina S, Solaro C, Righini I, et al. Sativex in resistant multiple sclerosis spasticity: discontinuation study in a large population of Italian patients (SA.FE. study). PLoS One. 2017;12(8):e0180651.
- Bever CT Jr. Multiple Sclerosis: symptomatic Treatment. Curr Treat Options Neurol. 1999 Jul;1(3):221–238.
- Pollmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs. 2008;22(4):291–324.
- Nance PW, Sheremata WA, Lynch SG, et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol. 1997 Jun;54(6):731–736.
- Smith C, Birnbaum G, Carter JL, et al. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology. 1994 Nov;44(11Suppl 9):S34–42. discussion S42-3.
- United Kingdom Tizanidine Trial Group. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology. 1994 Nov;44(11Suppl 9):S70–8.
- Baclofen monograph. [cited 2020 Apr 9]. Available from: https://www.drugs.com/monograph/baclofen.html; 2020.
- Brar SP, Smith MB, Nelson LM, et al. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Arch Phys Med Rehabil. 1991 Mar;72(3):186–189.
- Sachais BA, Logue JN, Carey MS. Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. Arch Neurol. 1977 Jul;34(7):422–428.
- Food and Drug Administration (FDA). Baclofen. [cited 2020 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208193s000lbl.pdf
- European Medicines Agency (EMA). Baclofen. [cited 2020 Apr 9]. Available from: https://www.ema.europa.eu/en/documents/psusa/baclofen-list-nationally-authorised-medicinal-products-psusa/00000293/201601_en.pdf
- Erwin A, Gudesblatt M, Bethoux F, et al. Intrathecal baclofen in multiple sclerosis: too little, too late? Mult Scler. 2011 May;17(5):623–629.
- Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med. 1989 Jun 8;320(23):1517–1521.
- Dario A, Tomei G. Management of spasticity in multiple sclerosis by intrathecal baclofen. Acta Neurochir Suppl. 2007;97(Pt 1):189–192.
- Sadiq SA, Poopatana CA. Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity. J Neurol. 2007 Oct;254(10):1464–1465.
- Romijn JA, van Lieshout JJ, Velis DN. Reversible coma due to intrathecal baclofen. Lancet. 1986 Sep 20;2(8508):696.
- Reeves RK, Stolp-Smith KA, Christopherson MW. Hyperthermia, rhabdomyolysis, and disseminated intravascular coagulation associated with baclofen pump catheter failure. Arch Phys Med Rehabil. 1998 Mar;79(3):353–356.
- Schmidt RT, Lee RH, Spehlmann R. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J Neurol Neurosurg Psychiatry. 1976 Apr;39(4):350–356.
- De Jongh DK. Remarks on the mechanism of analgesic action of morphine. Acta Physiol Pharmacol Neerl. 1954;3(2):164–172.
- Bujarski S, MacKillop J, Ray LA. Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study. Exp Clin Psychopharmacol. 2012 Jun;20(3):181–190.
- Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010 Aug;68(2):145–150.
- Kalman S, Osterberg A, Sorensen J, et al. Morphine responsiveness in a group of well-defined multiple sclerosis patients: a study with i.v. morphine. Eur J Pain. 2002;6(1):69–80.
- Food and Drug Administration (FDA). Morphine Sulfate injection. [cited 2020 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202515s000lbl.pdf
- Food and Drug Administration (FDA). Naltrexone hydrochloride tablets 50 mg. [cited 2020 Apr 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018932s017lbl.pdf
- Amatya B, Young J, Khan F. Do non-pharmacological interventions improve chronic pain in multiple sclerosis? - A Cochrane Review summary with commentary. NeuroRehabilitation. 2019;45(2):291–293.
- Cordella R, Franzini A, La Mantia L, et al. Hypothalamic stimulation for trigeminal neuralgia in multiple sclerosis patients: efficacy on the paroxysmal ophthalmic pain. Mult Scler. 2009 Nov;15(11):1322–1328.
- Roy HA, Aziz TZ. Deep brain stimulation and multiple sclerosis: therapeutic applications. Mult Scler Relat Disord. 2014 Jul;3(4):431–439.
- Deer TR, Mekhail N, Provenzano D, et al. The appropriate use of neurostimulation of the spinal cord and peripheral nervous system for the treatment of chronic pain and ischemic diseases: the Neuromodulation Appropriateness Consensus Committee. Neuromodulation. 2014 Aug;17(6):515–550. discussion 550.
- Berra E, Bergamaschi R, De Icco R, et al. The Effects of Transcutaneous Spinal Direct Current Stimulation on Neuropathic Pain in Multiple Sclerosis: clinical and Neurophysiological Assessment. Front Hum Neurosci. 2019;13:31.
- Demaneuf T, Aitken Z, Karahalios A, et al. Effectiveness of Exercise Interventions for Pain Reduction in People With Multiple Sclerosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Arch Phys Med Rehabil. 2019 Jan;100(1):128–139.
- Corallo F, Bonanno L, Di Cara M, et al. Therapeutic adherence and coping strategies in patients with multiple sclerosis: an observational study. Medicine (Baltimore). 2019 Jul;98(29):e16532.
- Miller E, Morel A, Redlicka J, et al. Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis. Curr Neuropharmacol. 2018;16(4):475–483.
- Simpson R, Simpson S, Ramparsad N, et al. Effects of Mindfulness-based interventions on physical symptoms in people with multiple sclerosis - a systematic review and meta-analysis. Mult Scler Relat Disord. 2019 Nov;9(38):101493.
- Kabat-Zinn J. An outpatient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation: theoretical considerations and preliminary results. Gen Hosp Psychiatry. 1982 4;Apr(1):33–47.
- Archibald CJ, McGrath PJ, Ritvo PG, et al. Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. Pain. 1994 Jul;58(1):89–93.
- Blyth FM, March LM, Cousins MJ. Chronic pain-related disability and use of analgesia and health services in a Sydney community. Med J Aust. 2003 Jul 21;179(2):84–87.
- Ehde DM, Gibbons LE, Chwastiak L, et al. Chronic pain in a large community sample of persons with multiple sclerosis. Mult Scler. 2003 Dec;9(6):605–611.
- Jensen MP, Romano JM, Turner JA, et al. Patient beliefs predict patient functioning: further support for a cognitive-behavioural model of chronic pain. Pain. 1999 May;81(1–2):95–104.
- Solaro C, Uccelli MM. Management of pain in multiple sclerosis: a pharmacological approach. Nat Rev Neurol. 2011 Aug 16;7(9):519–527.
- Lienau FS, Fullgraf H, Moser A, et al. Why do cannabinoids not show consistent effects as analgetic drugs in multiple sclerosis? Eur J Neurol. 2007 Oct;14(10):1162–1169.
- Nielsen S, Germanos R, Weier M, et al. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Curr Neurol Neurosci Rep. 2018 Feb 13;18(2):8.
- Haythornthwaite JA, Benrud-Larson LM. Psychological aspects of neuropathic pain. Clin J Pain. 2000 Jun;16(2 Suppl):S101–5.
- Saverino A, Solaro C. Pain in individuals with multiple sclerosis, knee prosthesis, and post-herpetic neuralgia: learning from focus group patients’ experience. Clin J Pain. 2012 May;28(4):300–308.
- Marrie RA, Horwitz RI, Cutter G, et al. Association between comorbidity and clinical characteristics of MS. Acta Neurol Scand. 2011 Aug;124(2):135–141.